

ForPatients

by Roche

Non Hodgkin Lymphoma (NHL)

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

Trial Status

Active, not recruiting

Trial Runs In

1 Countries

Trial Identifier

NCT05207670 ML43389

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma [NHL]).

Genentech, Inc.

Sponsor

Phase 2

Phase

NCT05207670 ML43389

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No
